FBN2: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: FBN2

NCBI ID: G2201

FBN2

FBN2: A Potential Drug Target Or Biomarker for Various Diseases

FBN2 (FBN2_HUMAN), a protein that is expressed in the human placenta, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

FBN2 is a member of the fibrillin-1 gene family, which encodes a protein that is involved in cell signaling and tissue structure. The fibrillin-1 gene has four splice variants, FBN1, FBN2, FBN3, and FBN4, of which only FBN2 is expressed in the placenta.

The Placenta plays a vital role in the development and maintenance of fetal growth and development. It is a complex organ that is formed from the fusion of two separate yolk sacs, each of which contains a different type of fibrillin-1 gene. The placenta is responsible for providing nutrients and oxygen to the developing fetus, as well as removing waste products from the body.

Studies have shown that FBN2 is involved in the formation and maintenance of the placenta. It is expressed in the cytoplasm and the endoplasmic reticulum of the placenta, and it has been shown to be involved in the development and maintenance of the placenta by regulating the formation of new vasculature and the formation of the placenta itself.

FBN2 has also been shown to be involved in the regulation of fetal growth and development. It has been shown to be involved in the production of growth factors, such as Git, which is a critical regulator of cell growth and differentiation. FBN2 has also been shown to be involved in the regulation of Angiogenesis, the process by which new blood vessels are formed.

In addition to its role in fetal development, FBN2 has also been shown to be involved in the regulation of adult tissue growth and regeneration. It has been shown to be involved in the regulation of cell signaling and differentiation, as well as in the regulation of tissue repair and regeneration.

FBN2 has also been shown to be involved in the regulation of inflammation. It has been shown to be involved in the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6. These cytokines have been shown to play a vital role in the regulation of immune responses and inflammation.

In addition to its role in inflammation, FBN2 has also been shown to be involved in the regulation of pain perception. It has been shown to be involved in the regulation of pain signaling, as well as in the regulation of neurotransmitter release.

Given its involvement in the regulation of fetal development, growth, and inflammation, FBN2 has potential as a drug target or biomarker for a variety of diseases. It is currently being targeted by researchers for the treatment of various neurological and cardiovascular diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

Research has shown that inhibiting FBN2 can lead to a variety of beneficial effects in these diseases. For example, studies have shown that inhibiting FBN2 can lead to a reduction in the growth of cancer cells, as well as a reduction in neurodegenerative disorder symptoms such as tremors and stiffness.

In addition to its potential as a drug target or biomarker, FBN2 is also of interest as a potential biomarker for certain diseases. The FBN2 gene has been shown to be expressed in a variety of tissues and organs, including the brain, heart, and liver. This suggests that FBN2 may be a useful biomarker for certain diseases, such as cancer, neurodegenerative disorders, or cardiovascular diseases.

Overall, FBN2 is a protein that has significant potential as a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in fetal development, growth, and inflammation, as well as its potential as a biomarker for certain diseases.

Protein Name: Fibrillin 2

Functions: Fibrillins are structural components of 10-12 nm extracellular calcium-binding microfibrils, which occur either in association with elastin or in elastin-free bundles. Fibrillin-2-containing microfibrils regulate the early process of elastic fiber assembly. Regulates osteoblast maturation by controlling TGF-beta bioavailability and calibrating TGF-beta and BMP levels, respectively

The "FBN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets